Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001012975-15-000485
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-06-12 16:58:12
Reporting Period:
2015-06-11
Filing Date:
2015-06-12
Accepted Time:
2015-06-12 16:58:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1586049 Oxford Immunotec Global Plc OXFD In Vitro & In Vivo Diagnostic Substances (2835) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1249153 Dennis Henner C/o Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252522 Nicholas Galakatos C/o Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252523 Robert Liptak C/o Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1252525 Kurt Wheeler C/o Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431403 Nicholas Simon C/o Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431441 Clarus Ventures I, Llc C/o Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431445 Clarus Lifesciences I, L.p. C/o Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1505590 Clarus Ventures I Management, L.p. C/o Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2015-06-11 25,168 $14.27 2,285,037 No 4 S Direct
Ordinary Shares Disposition 2015-06-12 6,430 $14.25 2,278,607 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Securities held of record by Clarus Lifesciences I, L.P. ("Clarus"). Clarus Ventures I Management, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. Clarus Ventures I, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLP, GPLLC and Messrs. Galakatos, Henner, Liptak, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.
  2. The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $14.25 to $14.39 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.